NASDAQ:ALDX Aldeyra Therapeutics Q3 2025 Earnings Results & Report $0.63 -0.02 (-3.27%) Closing price 11/12/2026 04:00 PM EasternExtended Trading$0.63 +0.00 (+0.30%) As of 11/12/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aldeyra Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$0.13 versus the -$0.17 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call4:00 PM ET Aldeyra Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.17Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAldeyra Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$24.25 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Aldeyra Therapeutics Q3 2025 Earnings FAQ Did Aldeyra Therapeutics beat earnings estimates for Q3 2025? Aldeyra Therapeutics (NASDAQ:ALDX) reported earnings of -$0.13 per share for Q3 2025, beating the consensus estimate of -$0.17. The report was announced on Wednesday, November 5, 2025. Aldeyra Therapeutics Earnings HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Claritev (CTEV), Aldeyra Therapeutics (ALDX) and Argenx Se (ARGX)November 11 at 6:28 PM | theglobeandmail.comAldeyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading. | Traders Agency (Ad)Aldeyra Therapeutics (ALDX) Projected to Release Earnings on WednesdayNovember 3, 2026 | americanbankingnews.comAldeyra Therapeutics, Inc. Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye DiseaseSeptember 29, 2026 | marketscreener.comMAldeyra Therapeutics plans formal FDA dispute resolution request for Reproxalap after third complete response letterSeptember 29, 2026 | msn.comSee More Aldeyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email. Email Address About Aldeyra TherapeuticsAldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases. Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis. Aldeyra has also evaluated additional RASP-targeting compounds and has pursued ophthalmic treatments for other diseases involving inflammation and immune dysregulation. Founded in 2008 and headquartered in Lexington, Massachusetts, Aldeyra conducts clinical development activities intended to support potential commercialization in the United States and international markets. The company is led by Todd C. Brady, M.D., Ph.D., who serves as president and chief executive officer. As a development-stage biotechnology company, Aldeyra’s products remain subject to clinical, regulatory, and commercial uncertainties.View Aldeyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
